BioCentury | Apr 20, 2020
Finance

French VC Sofinnova expanding start-up ecosystem in Italy with new local fund’s first investments

...Seghezzi said has been one of the country’s strengths historically. For example, EU-approved gene therapy Strimvelis...
...in 2016 to treat severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), then sold Strimvelis...
BioCentury | Sep 4, 2019
Company News

Novartis’ early collaboration with NICE key to rapid response on Luxturna

...weeks faster than it did for the first gene therapy to receive a positive recommendation, Strimvelis...
...retinal pigment epithelium-specific protein 65kDa (RPE65) gene. NICE also used the HST process to review Strimvelis...
...ADA-SCID), a process that took about seven months, or 28 weeks (see " NICE Recommends Strimvelis...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...$7.0 $6.7 4% Gene therapies Orchard Therapeutics plc (NASDAQ:ORTX) Licensed from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) Strimvelis...
BioCentury | Jun 17, 2019
Company News

Trial data suggest 80% of Zynteglo patients could meet milestones in outcomes-based pricing model

...of life and life extension estimates. In contrast, the least expensive of the five therapies, Strimvelis...
BioCentury | May 18, 2019
Product Development

AAVs on the brink: Charting the clinical landscape of in vivo gene therapies

...big jump between 2016 and 2017, possibly a response to the approval of GlaxoSmithKline plc’s Strimvelis...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...programs in 2018, has six candidates in human trials and markets ex vivo gene therapy Strimvelis...
BioCentury | Mar 2, 2019
Product Development

Roche broadens its BD scope

...therapy programs, has six candidates in human trials. It also markets ex vivo gene therapy Strimvelis...
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

...to gain GlaxoSmithKline plc's Orphan disease gene therapy pipeline last April. The GSK portfolio included Strimvelis...
BioCentury | Nov 2, 2018
Financial News

Orchard achieves $1.2B valuation with $200M IPO

...31, closing at $14. Proceeds from the IPO will be used to fund commercialization of Strimvelis...
...the second half of 2020. It had raised about $290 million prior to the IPO. Strimvelis...
...PacGrow. Orchard Therapeutics Ltd. (NASDAQ:ORTX), London, U.K. Jennie Walters OTL-103 (2696275, GSK2696275) OTL-200 (2696274, GSK2696274) OTL-300 (2696277, GSK2696277) Strimvelis (2696273, GSK2696273) GlaxoSmithKline...
BioCentury | Oct 31, 2018
Financial News

Orchard achieves $1.2B valuation with $200M IPO

...Wednesday, closing at $14. Proceeds from the IPO will be used to fund commercialization of Strimvelis...
...the second half of 2020. It had raised about $290 million prior to the IPO. Strimvelis...
...Sachs, Cowen and Wedbush PacGrow. Jennie Walters EFS lentiviral gene therapy (OTL-101) OTL-103 (2696275, GSK2696275) OTL-200 (2696274, GSK2696274) Strimvelis (2696273, GSK2696273) GlaxoSmithKline...
Items per page:
1 - 10 of 41